Dutch Pharmacogenetics Working Group (DPWG) Guidelines for Gene-Drug Interaction Between UGT1A1 and Irinotecan – European Journal of Human Genetics

Swen J, Wilting I, Goede A, de, Grandia L, Mulder H, Touw D, and others Pharmacogenetics: From Bench to Byte. Clin Pharm Ther. 2008;83:781–7. https://doi.org/10.1038/sj.clpt.6100507.

Google Scholar article

Guchelaar HJ. Pharmacogenomics, a new section of the European Journal of Human Genetics. Eur J Hum Genet. 2018;26:1399–400. https://doi.org/10.1038/s41431-018-0205-4.

PubMed Article PubMed Central Google Scholar

Lunenburg CATC, van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk AM, et al. Dutch Pharmacogenetics Working Group (DPWG) guidelines for the gene-drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet. 2020;28:508–17. https://doi.org/10.1038/s41431-019-0540-0.

PubMed Google Scholar article

Matic M, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Houwink EJF, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). Eur J Hum Genet. 2021. https://doi.org/10.1038/s41431-021-00920-y.

Brouwer JMJL, Nijenhuis M, Soree B, Guchelaar HJ, Swen JJ, van Schaik RHN, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs . Eur J Hum Genet. 2021. https://doi.org/10.1038/s41431-021-01004-7.

Rougier P, Bugat R. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol. 1996;23:34–41.

Google Scholar PubMed

Rothenberg ML. Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin Oncol. 1998;25:39–46.

Google Scholar PubMed

[ PubMed ]Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of reduced bilirubin UDP-glucuronosyltransferase 1 expression in Gilbert’s syndrome. N. Engl J Med. 1995;333:1171–5. https://doi.org/10.1056/nejm199511023331802.

PubMed Google Scholar article

UGT1A1 allele nomenclature nd https://www.pharmacogenomics.pha.ulaval.ca/wp-content/uploads/2015/04/UGT1A1-allele-nomenclature.html (accessed September 6, 2021).

Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance in human protein-coding genes. BioRxiv. 2019:531210. https://doi.org/10.1101/531210.

Akiyama Y, Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, et al. Genetic testing for UGT1A1*28 and *6 in Japanese patients receiving irinotecan chemotherapy. Anne Oncol. 2008;19:2089–90. https://doi.org/10.1093/announce/mdn645.

PubMed Article PubMed Central Google Scholar

Teh LK, Hashim H, Zakaria ZA, Salleh MZ. Polymorphisms of UGT1A1*6, UGT1A1*27 and UGT1A1*28 in three major ethnic groups of Malaysia. Indian J Med Res. 2012;136:249–59.

PubMed PubMed Central Google Scholar

Sung C, Lee PL, Tan LL, Toh DSL. Pharmacogenetic risk of adverse reactions to irinotecan in major ethnic populations in Singapore. Safe medicine. 2011;34:1167–75. https://doi.org/10.2165/11594440-000000000-00000.

PubMed Google Scholar article

Akaba K, Kimura T, Sasaki A, Tanabe S, Ikegami T, Hashimoto M, et al. Neonatal hyperbilirubinemia and bilirubin uridine diphosphate-glucuronosyltransferase gene mutation: a common missense mutation among Japanese, Koreans and Chinese. Biochem Mol Biol Int. 1998;46:21–6. https://doi.org/10.1080/15216549800203512.

PubMed Google Scholar article

de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of irinotecan therapy: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 2018;57:1229–54. https://doi.org/10.1007/s40262-018-0644-7.

PubMed Article PubMed Central Google Scholar

Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, Kuffel MA, et al. UGT1A1 genotype-guided phase i study of irinotecan, oxaliplatin and capecitabine. Invest N. Drugs. 2013;31:1559–67. https://doi.org/10.1007/s10637-013-0034-9.

Google Scholar article

Denlinger CS, Blanchard R, Xu L, Bernaards C, Litwin S, Spittle C, et al. Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharm. 2009;65:97–105. https://doi.org/10.1007/s00280-009-1008-7.

Google Scholar article

Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002;2:43–7. https://doi.org/10.1038/sj.tpj.6500072.

PubMed Google Scholar article

de Jong FA, Kehrer DFS, Mathijssen RHJ, Creemers G, de Bruijn P, van Schaik RHN, et al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo‐controlled study. Oncologist. 2006;11:944–54. https://doi.org/10.1634/theoncologist.11-8-944.

PubMed Google Scholar article

Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RHJ, Verweij J, et al. Influence of genetic variants in UGT1A1 and UGT1A9 on in vivo glucuronidation of SN-38. J Clin Pharm. 2004;44:854–60. https://doi.org/10.1177/0091270004267159.

Google Scholar article

Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia from irinotecan. J Clin Oncol. 2004;22:1382–8. https://doi.org/10.1200/JCO.2004.07.173.

PubMed Google Scholar article

Hulshof EC, de With M, de Man FM, Creemers GJ, Deiman BALM, Swen JJ, et al. Irinotecan dosing guided by UGT1A1 genotype: prospective analysis of safety and costs in poor metabolizer patients. Eur J Cancer. 2022;162:148–57. https://doi.org/10.1016/J.EJCA.2021.12.009.

PubMed Google Scholar article

Hu ZY, Yu Q, Pei Q, Guo C. Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin Cancer Res. 2010;16:3832–42. https://doi.org/10.1158/1078-0432.CCR-10-1122.

PubMed Google Scholar article

Liu X, Cheng D, Kuang Q, Liu G, Xu W. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J. 2014;14:120–9. https://doi.org/10.1038/tpj.2013.10.

PubMed Google Scholar article

Lu CY, Huang CW, Wu IC, Tsai HL, Ma CJ, Yeh YS, et al. Clinical implication of UGT1A1 promoter polymorphism for irinotecan dose escalation in patients with metastatic colorectal cancer treated with bevacizumab plus first-line FOLFIRI. Translation Oncol. 2015;8:474–9. https://doi.org/10.1016/j.tranon.2015.11.002.

PubMed Article PubMed Central Google Scholar

Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, et al. Pharmacokinetics/pharmacodynamics of irinotecan and genetic polymorphisms of UGT1A in Japanese: roles of UGT1A1*6 and *28. Pharmacogenetic genomics. 2007;17:497–504. https://doi.org/10.1097/FPC.0b013e328014341f.

PubMed Google Scholar article

Pirmohamed M, Hughes DA. Pharmacogenetic testing: the need for a level playing field. Nat Rev Drug Discov. 2013;12:3–4. https://doi.org/10.1038/nrd3921.

Swen JJ, Huizinga TW, Gelderblom H, de Vries EGE, Assendelft WJJ, Kirchheiner J, et al. Translation of pharmacogenomics: challenges on the road to the clinic. PLoS Med. 2007;4:e209. https://doi.org/10.1371/journal.pmed.0040209.

PubMed Article PubMed Central Google Scholar

Swen JJ, Nijenhuis M, van Rhenen M, de Boer-Veger NJ, Buunk AM, Houwink EJF, and others Pharmacogenetic information in clinical guidelines: The European perspective. Clin Pharm Ther. 2018;103:795–801. https://doi.org/10.1002/cpt.1049.

Google Scholar article

Etienne-Grimaldi MC, Boyer JC, Thomas F, Quaranta S, Picard N, Loriot MA, et al. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundam Clin Pharm. 2015;29:219–37. https://doi.org/10.1111/fcp.12117.

Google Scholar article

AIOM-SIF. Recommendations for pharmacogenetic analyzes nd https://www.aiom.it/raccomandazioni-2019-per-analisi-farmacogenetiche/ (accessed November 15, 2021).

Stanford University and St. Jude Children’s Research Hospital. Clinical Pharmacogenetics Implementation Consortium. PharmGKB PGRN 2020. https://cpicpgx.org/ (accessed May 8, 2020).